MCID: PRS042
MIFTS: 44

Prostate Disease

Categories: Endocrine diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 42 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hypertrophy and prostatic hyperplasia, benign, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3), and among its related pathways/superpathways is Transcription Androgen Receptor nuclear signaling. The drugs Povidone-iodine and Povidone have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and testes.

Wikipedia : 74 The prostate is an exocrine gland of the male reproductive system in most mammals. It differs... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 125, show less)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 32.2 SRD5A1 KLK3 AR
2 prostatic hyperplasia, benign 32.1 SRD5A1 KLK3 CDKN2B-AS1 AR
3 prostatic adenoma 31.9 SRD5A1 KLK3
4 prostate cancer 31.2 TERC SRD5A1 SCHLAP1 PTENP1 PRNCR1 PCGEM1
5 impotence 31.1 SRD5A1 KLK3 AR
6 suppression of tumorigenicity 12 31.0 PCA3 KLK3 FOLH1 AR
7 bladder cancer 30.6 TERC SCHLAP1 PCAT1 MEG3 MALAT1 H19
8 gynecomastia 30.5 SRD5A1 KLK3 AR
9 alopecia, androgenetic, 1 30.4 SRD5A1 AR
10 renal cell carcinoma, nonpapillary 30.4 SCHLAP1 PTENP1 MALAT1 LINC00963 H19 GAS5
11 prostatitis 11.0
12 prostate neuroendocrine neoplasm 10.8 KLK3 FOLH1 AR
13 androgenic alopecia 10.8 SRD5A1 KLK3 AR
14 sex development disorder 10.8 SRD5A1 KLK3 AR
15 prostate adenoid cystic carcinoma 10.8 KLK3 AR
16 prostate leiomyoma 10.8 KLK3 AR
17 bladder urothelial carcinoma 10.8 SRD5A1 MEG3 MALAT1 KLK3 GAS5 AR
18 thyroid cancer, nonmedullary, 1 10.7 MALAT1 H19 GAS5
19 submandibular gland cancer 10.7 KLK3 AR
20 prostatic acinar adenocarcinoma 10.7 KLK3 AR
21 coronary heart disease 1 10.7 IGF2-AS H19 GAS5 CDKN2B-AS1
22 androgen insensitivity, partial 10.7 SRD5A1 AR
23 glioma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1 CBR3-AS1
24 osteogenic sarcoma 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
25 glioma susceptibility 1 10.7 PCAT1 MEG3 MALAT1 LINC00963 H19 GAS5
26 prostate stromal sarcoma 10.7 PCA3 KLK3
27 osteoarthritis 10.7 PCGEM1 MEG3 H19 GAS5
28 myeloma, multiple 10.7 PCAT1 MEG3 MALAT1 H19 GAS5
29 cervical cancer 10.7 TERC PCAT1 MEG3 MALAT1 H19 GAS5
30 malignant glioma 10.7 PRNCR1 PCGEM1 MEG3 MALAT1 LINC00963 H19
31 astrocytoma 10.7 PCA3 H19 GAS5 CDKN2B-AS1
32 endometrial cancer 10.7 TERC PTENP1 MEG3 KLK3 H19 GAS5
33 gallbladder cancer 10.7 MEG3 MALAT1 H19 CDKN2B-AS1
34 squamous cell carcinoma 10.7 PCAT1 MALAT1 H19 CDKN2B-AS1 CBR3-AS1
35 esophageal cancer 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
36 nasopharyngeal carcinoma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
37 wilms tumor 1 10.6 MEG3 IGF2-AS H19 AR
38 pseudovaginal perineoscrotal hypospadias 10.6 SRD5A1 AR
39 gastric cancer 10.6 TERC PTENP1 PRNCR1 PCAT1 MEG3 MALAT1
40 laryngeal squamous cell carcinoma 10.6 MALAT1 H19 CDKN2B-AS1
41 vulva squamous cell carcinoma 10.6 MEG3 MALAT1
42 kidney cancer 10.6 MEG3 MALAT1 H19 GAS5
43 hepatocellular carcinoma 10.6 TERC PTENP1 PCAT1 MEG3 MALAT1 IGF2-AS
44 polycystic ovary syndrome 10.6 SRD5A1 GAS5 AR
45 withdrawal disorder 10.5 KLK3 AR
46 pituitary adenoma 10.5 MEG3 MALAT1 H19
47 diabetic cataract 10.5 MALAT1 AR
48 villous adenoma 10.4 KLK3 FOLH1
49 meningioma, radiation-induced 10.2 MEG3 H19
50 adenoma 10.1
51 adenocarcinoma 10.0
52 spinal cord injury 9.8
53 overgrowth syndrome 9.8
54 vesicoureteral reflux 1 9.7
55 insulin-like growth factor i 9.7
56 body mass index quantitative trait locus 11 9.7
57 body mass index quantitative trait locus 9 9.7
58 body mass index quantitative trait locus 8 9.7
59 body mass index quantitative trait locus 4 9.7
60 body mass index quantitative trait locus 10 9.7
61 body mass index quantitative trait locus 7 9.7
62 body mass index quantitative trait locus 12 9.7
63 body mass index quantitative trait locus 14 9.7
64 body mass index quantitative trait locus 18 9.7
65 pachyonychia congenita 3 9.7
66 body mass index quantitative trait locus 19 9.7
67 body mass index quantitative trait locus 20 9.7
68 sexual disorder 9.7
69 pyelonephritis 9.7
70 neurogenic bladder 9.7
71 acute cystitis 9.7
72 cystitis 9.7
73 acromegaly 9.7
74 neurofibromatosis, type ii 9.6
75 alcohol dependence 9.6
76 hypercholesterolemia, familial, 1 9.6
77 migraine with or without aura 1 9.6
78 schistosoma mansoni infection, susceptibility/ 9.6
79 strabismus 9.6
80 thrombophilia due to thrombin defect 9.6
81 myopathy, myosin storage, autosomal recessive 9.6
82 periodontitis, chronic 9.6
83 aging 9.6
84 myocardial infarction 9.6
85 prostate cancer, hereditary, 3 9.6
86 obstructive nephropathy 9.6
87 bone disease 9.6
88 bacterial infectious disease 9.6
89 hydronephrosis 9.6
90 prostatic cyst 9.6
91 disseminated intravascular coagulation 9.6
92 heart disease 9.6
93 infant gynecomastia 9.6
94 conn's syndrome 9.6
95 male infertility 9.6
96 rectal disease 9.6
97 nodular prostate 9.6
98 schistosomiasis 9.6
99 pyuria 9.6
100 papilledema 9.6
101 alcohol use disorder 9.6
102 urethral stricture 9.6
103 hypogonadism 9.6
104 leiomyosarcoma 9.6
105 cerebral palsy 9.6
106 rectum cancer 9.6
107 transitional cell carcinoma 9.6
108 proctitis 9.6
109 lipid metabolism disorder 9.6
110 ischemia 9.6
111 skin disease 9.6
112 urinary tract obstruction 9.6
113 infertility 9.6
114 paraplegia 9.6
115 radiation cystitis 9.6
116 hypogonadotropism 9.6
117 periodontitis 9.6
118 mechanical strabismus 9.6
119 diabetes mellitus 9.6
120 hemorrhoid 9.6
121 48,xyyy 9.6
122 precocious puberty 9.6
123 spasticity 9.6
124 radiation proctitis 9.6
125 pik3ca-related overgrowth syndrome 9.6

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN): (showing 2, show less)


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


tremor, angina pectoris, equilibration disorder, prostatism

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 66, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone-iodine Approved Phase 4 25655-41-8
2
Povidone Approved Phase 4 9003-39-8
3
Iodine Approved, Investigational Phase 4 7553-56-2 807
4
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
5
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
6 Anti-Infective Agents Phase 4
7 Anti-Infective Agents, Local Phase 4
8 cadexomer iodine Phase 4
9 Plasma Substitutes Phase 4
10 Blood Substitutes Phase 4
11 Hormone Antagonists Phase 4
12 Hormones Phase 4
13 Androgens Phase 4
14 Hypoglycemic Agents Phase 4
15 Fenugreek seed meal Phase 4
16 Fenugreek Phase 4
17
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
18
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
19
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
20 Vasodilator Agents Phase 3
21 Phosphodiesterase 5 Inhibitors Phase 3
22 Phosphodiesterase Inhibitors Phase 3
23 Adrenergic Antagonists Phase 3
24 Neurotransmitter Agents Phase 3
25 Adrenergic alpha-Antagonists Phase 3
26 Adrenergic Agents Phase 3
27 Steroid Synthesis Inhibitors Phase 3
28 5-alpha Reductase Inhibitors Phase 3
29
Ethanol Approved Phase 1, Phase 2 64-17-5 702
30
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
31
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
32
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
33
nivolumab Approved Phase 1, Phase 2 946414-94-4
34
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
35
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
36 Onapristone Investigational Phase 1, Phase 2 96346-61-1
37 Immunologic Factors Phase 1, Phase 2
38 Androgen Antagonists Phase 1, Phase 2
39 Central Nervous System Depressants Phase 1, Phase 2
40 Imatinib Mesylate Phase 2 220127-57-1 123596
41 Protein Kinase Inhibitors Phase 2
42 Vaccines Phase 2
43 Fertility Agents Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Prolactin Release-Inhibiting Factors Phase 2
46 Antibodies, Monoclonal Phase 1, Phase 2
47 Immunoglobulin G Phase 1, Phase 2
48 Antibodies Phase 1, Phase 2
49 Immunoglobulins Phase 1, Phase 2
50 Epothilones Phase 2
51 Antimitotic Agents Phase 2
52 Antineoplastic Agents, Immunological Phase 2
53
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
54 Cola Phase 1
55 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
56 Hops Approved
57
Octreotide Approved, Investigational 83150-76-9 6400441 383414
58
Lidocaine Approved, Vet_approved 137-58-6 3676
59
Ciprofloxacin Approved, Investigational 85721-33-1 2764
60
Lactitol Investigational 585-88-6, 585-86-4 493591
61 Anesthetics, Local
62 Fibrinolytic Agents
63 Plasminogen
64 Gastrointestinal Agents
65 Follicle Stimulating Hormone
66 Anesthetics

Interventional clinical trials:

(showing 51, show less)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
3 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00827242 Phase 3 Placebo;tadalafil
5 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
6 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
7 A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. Unknown status NCT00895466 Phase 1, Phase 2
8 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
9 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
10 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
11 A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy Completed NCT01431391 Phase 2 leuprolide acetate
12 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer Recruiting NCT03543189 Phase 1, Phase 2 Nivolumab;Androgen Deprivation Therapy
13 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
14 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
15 A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate Terminated NCT00448097 Phase 2 cetuximab;docetaxel
16 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy Withdrawn NCT03658408 Phase 2 4-aminopyridine;placebo
17 A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy Withdrawn NCT02065323 Phase 2 Standard ADT;Dovitinib
18 Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy Completed NCT01307852 Phase 1
19 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
20 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
21 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
22 Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China Unknown status NCT01590498
23 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Unknown status NCT03192917
24 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) Completed NCT01826617
25 Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00941343 Alfuzosin (XATRAL® - SL770499)
26 Intratesticular Hormone Levels in Healthy Young Men Completed NCT00756561
27 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907
28 Validation of a Semiquantitative Screening Assay for PSA Completed NCT00853710
29 Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy Completed NCT01762241
30 Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery Completed NCT00484783
31 Prostatic Artery Embolization for Benign Prostatic Obstruction Completed NCT03099421
32 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
33 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
34 Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy Completed NCT00407329
35 Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly Completed NCT00616408 Octreotide-LAR
36 2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection Completed NCT01886547
37 Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer Recruiting NCT03350529
38 MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer Recruiting NCT04026763
39 Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging Recruiting NCT03711643
40 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
41 Contrast Enhanced MRI of the Prostate Recruiting NCT02245282
42 Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men Recruiting NCT04134130 Degarelix 120 MG [Firmagon];Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector;Testosterone Undecanoate
43 Biobank for African American Prostate Cancer Research in Florida Recruiting NCT03232411
44 Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease Recruiting NCT04024475
45 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
46 Molecular Studies and Clinical Correlations in Human Prostatic Disease Active, not recruiting NCT00578240
47 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial Enrolling by invitation NCT03589196
48 Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at UCLA Enrolling by invitation NCT03503643
49 A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? Terminated NCT02031029
50 Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer Terminated NCT02307552
51 ConfirmMDx Assay is Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy Withdrawn NCT03597386

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

40
Prostate, Kidney, Testes, Bone, Spinal Cord, Liver, Smooth Muscle

Publications for Prostate Disease

Articles related to Prostate Disease:

(showing 1498, show less)
# Title Authors PMID Year
1
Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial. 42
31702643 2019
2
Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. 42
31727627 2019
3
Re: The Evaluation of Nocturia in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and the Analysis of the Curative Effect after Medical or Placebo Therapy for Nocturia: A Randomized Placebo-Controlled Study. 42
31766084 2019
4
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. 54 61
20351196 2010
5
Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. 61 54
19670261 2010
6
Psychological distress and prostate specific antigen levels in men with and without prostate cancer. 61 54
19486654 2009
7
Biomarkers for prostate cancer. 54 61
19507229 2009
8
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. 54 61
18627423 2009
9
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. 54 61
19375623 2009
10
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. 54 61
19128049 2009
11
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. 61 54
19030020 2009
12
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]. 61 54
19157222 2008
13
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 61 54
18668524 2008
14
5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. 54 61
18320593 2008
15
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. 61 54
18686378 2008
16
A preliminary study of the baboon prostate pathophysiology. 61 54
17639509 2007
17
Androgen receptor modulation: lessons learned from beyond the prostate. 61 54
17881894 2007
18
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. 54 61
17571482 2007
19
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 61 54
17159365 2007
20
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 61 54
17318358 2006
21
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. 61 54
16093978 2005
22
Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. 61 54
15956333 2005
23
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. 61 54
14532846 2003
24
Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. 61 54
12858359 2003
25
Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. 54 61
12962896 2003
26
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. 54 61
11903683 2001
27
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. 54 61
11720279 2001
28
[Urinary problems and prostate-specific antigen in a Norwegian normal population]. 61 54
11301608 2001
29
Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients. 61 54
11741128 2001
30
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. 54 61
11326656 2000
31
Polyarteritis nodosa mimicking prostatic cancer. 61 54
11036851 2000
32
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 61 54
11061535 2000
33
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]. 61 54
11107529 2000
34
Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. 61 54
10750886 2000
35
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. 54 61
10632336 1999
36
Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein. 61 54
10510889 1999
37
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. 61 54
9730460 1998
38
Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer. 54 61
9352130 1997
39
[Influence of age on serum prostate specific antigen concentration]. 54 61
9594181 1996
40
PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. 61 54
8638528 1996
41
Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. 61 54
8977078 1996
42
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. 61 54
7479385 1995
43
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 61 54
8750649 1995
44
Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. 54 61
8725043 1995
45
Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. 54 61
7521173 1994
46
[Variability of values of prostate-specific antigen determined with 6 methods]. 61 54
7514278 1994
47
Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. 61 54
7531895 1994
48
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]. 61 54
7685140 1993
49
[Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. 61 54
1721770 1991
50
[A mass screening of the prostatic diseases and serum prostate specific antigen]. 54 61
1720276 1991
51
Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. 54 61
1697014 1990
52
[The histological expression of prostate-specific antigen and its clinical significance in patients with prostate cancer]. 54 61
1698232 1990
53
Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. 61 54
1699766 1990
54
A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia. 61
31852153 2019
55
Prospective evaluation of urinary steroids and prostate carcinoma-induced deviation: preliminary results. 61
31833333 2019
56
Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. 61
31811242 2019
57
A review of microscopy-based evidence for the association of Propionibacterium acnes biofilms in degenerative disc disease and other diseased human tissue. 61
31359216 2019
58
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. 61
31530439 2019
59
Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men. 61
31454437 2019
60
Glycosylation products in prostate diseases. 61
31400314 2019
61
Multimodal feature learning and fusion on B-mode ultrasonography and sonoelastography using point-wise gated deep networks for prostate cancer diagnosis. 61
31743102 2019
62
Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation. 61
31271729 2019
63
Evaluation of canine prostate volume in calculated tomographic images - comparison of two assessment methods. 61
31640698 2019
64
Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. 61
31577095 2019
65
Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. 61
31633263 2019
66
Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. 61
31626149 2019
67
Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. 61
31376187 2019
68
[Detection of BRAF mutation in canine prostatic diseases]. 61
31627222 2019
69
Transcription regulators are transiently expressed during the prostate gland adaptation to the hypoandrogenic environment. 61
30912572 2019
70
Longitudinal changes in prostate volume in a community-based cohort study of middle-aged and elderly men in rural China. 61
31539457 2019
71
Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities. 61
31786882 2019
72
Design of a Clinical Decision Support System for Predicting Erectile Dysfunction in Men Using NHIRD Dataset. 61
30369456 2019
73
Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. 61
30683762 2019
74
Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. 61
31390729 2019
75
Caveolins; An Assailant or An Ally of Various Cellular Disorders. 61
30776841 2019
76
A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies. 61
31469635 2019
77
A temporal and spatial map of axons in developing mouse prostate. 61
30976911 2019
78
Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. 61
31300720 2019
79
Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. 61
30618413 2019
80
The prevalence and risk factors of prostatic calculi in Han Chinese: a cross-sectional study based on health examinations. 61
31156012 2019
81
Clinical approach to prostatic diseases in the dog. 61
30974484 2019
82
Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml-1). 61
31169140 2019
83
Treatment of Prostate Disease and Cognitive Problems. 61
31260607 2019
84
Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients with and without Prostate Cancer. 61
30676475 2019
85
Second-harmonic generation microscopy analysis reveals proteoglycan decorin is necessary for proper collagen organization in prostate. 61
31148435 2019
86
Prostate-Specific Antigen Within the Reference Range, Subclinical Coronary Atherosclerosis, and Cardiovascular Mortality. 61
30885050 2019
87
Prostate enlargement and altered urinary function are part of the aging process. 61
31085797 2019
88
Sperm epimutation biomarkers of obesity and pathologies following DDT induced epigenetic transgenerational inheritance of disease. 61
31186947 2019
89
Assessment of Glyphosate Induced Epigenetic Transgenerational Inheritance of Pathologies and Sperm Epimutations: Generational Toxicology. 61
31011160 2019
90
Incidence of prostate cancer among patients with prostate-related urinary symptoms: A single institution series in 10 years. 61
31040596 2019
91
Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. 61
31143671 2019
92
Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer. 61
30867737 2019
93
Sociodemographic factors that affect the real treatment rate among patients diagnosed with benign prostatic hyperplasia. 61
30857454 2019
94
Prostate cancer and prostatic diseases Best of China, 2018. 61
30518869 2019
95
Validation of canine prostate volumetric measurements in computed tomography determined by the slice addition technique using the Amira program. 61
30717756 2019
96
A folic acid-enriched diet attenuates prostate involution in response to androgen deprivation. 61
30298636 2019
97
Environmental Toxicant Induced Epigenetic Transgenerational Inheritance of Prostate Pathology and Stromal-Epithelial Cell Epigenome and Transcriptome Alterations: Ancestral Origins of Prostate Disease. 61
30778168 2019
98
Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men. 61
30840795 2019
99
Direct mechanical characterization of prostate tissue-a systematic review. 61
30225866 2019
100
Magnetic resonance imaging-guided transperineal prostate biopsy. 61
30964117 2019
101
Association between oral pathogens and prostate cancer: building the relationship. 61
30906801 2019
102
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue. 61
30591067 2018
103
Oxidative damage in patients with benign prostatic hyperplasia and prostate cancer co-exposed to phthalates and to trace elements. 61
30808488 2018
104
Role of PPAR-α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats. 61
29862557 2018
105
A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. 61
30566875 2018
106
Advances in Prostatic Diagnostics in Dogs: The Role of Canine Prostatic Specific Esterase in the Early Diagnosis of Prostatic Disorders. 61
30502858 2018
107
PITUITARY EVALUATION IN PATIENTS WITH LOW PROSTATE-SPECIFIC ANTIGEN. 61
30289304 2018
108
Accuracy of ultrasonography and fine-needle aspiration cytology in the diagnosis of prostate diseases in dogs. 61
30474330 2018
109
The distribution of BCG prostatitis: A clue for pathogenetic processes? 61
29987889 2018
110
CPSE determination and detection of canine prostatic diseases: The importance of a specific diagnosis. 61
29956380 2018
111
Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. 61
30374274 2018
112
Anti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice. 61
30118791 2018
113
Myeloperoxidase and Prostate volume: A preliminary study. 61
30042072 2018
114
[Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians]. 61
29574008 2018
115
Lycium chinense Mill improves hypogonadism via anti-oxidative stress and anti-apoptotic effect in old aged rat model. 61
30269620 2018
116
[Prostate artery embolisation is a new treatment for prostate disease]. 61
30084348 2018
117
Maternal protein malnutrition: effects on prostate development and adult disease. 61
29582717 2018
118
Operations for Suspected Neoplasms in a Resource-Limited Setting: Experience and Challenges in the Eastern Democratic of Congo. 61
29290072 2018
119
Diagnostic Performance and Interobserver Consistency of the Prostate Imaging Reporting and Data System Version 2: A Study on Six Prostate Radiologists with Different Experiences from Half a Year to 17 Years. 61
29998885 2018
120
A pilot study in intraparenchymal therapy delivery in the prostate: a comparison of delivery with a porous needle vs standard needle. 61
30055610 2018
121
Prostatic Calculi: Do They Matter? 61
29157875 2018
122
Canine Prostate Disease. 61
29933768 2018
123
Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males. 61
29947032 2018
124
Monocenter Experience with 532 Nm-Laser Photoselective-Vaporization of the Prostate by GreenLight XPS™ Laser: Is It Really an Endourological Joker Card? 61
29791696 2018
125
Unilateral upper extremity lymphedema in metastatic prostate cancer. 61
29881554 2018
126
[Analysis of the prevalence and related risk factors of prostate diseases in traffic policemen]. 61
30248739 2018
127
Homeostasis: apoptosis and cell cycle in normal and pathological prostate. 61
29730957 2018
128
Macrophage Cytokines Enhance Cell Proliferation of Normal Prostate Epithelial Cells through Activation of ERK and Akt. 61
29769604 2018
129
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. 61
29335762 2018
130
The malignancy index in plasma samples as a prostate cancer biomarker. 61
29906406 2018
131
An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. 61
29408166 2018
132
Canine prostate specific esterase (CPSE) as an useful biomarker in preventive screening programme of canine prostate: CPSE threshold value assessment and its correlation with ultrasonographic prostatic abnormalities in asymptomatic dogs. 61
29164718 2018
133
20 years-A retrospective of prostate cancer and prostatic diseases. 61
29259294 2018
134
Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? 61
29117997 2018
135
Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. 61
29523809 2018
136
Setting up a service for men with benign prostate disease. 61
29561636 2018
137
Association between male pattern baldness and prostate disease: A meta-analysis. 61
29054497 2018
138
Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. 61
29226351 2018
139
Extraction, purification of prostate-specific antigen (PSA), and establishment of radioimmunoassay system as a diagnostic tool for prostate disorders. 61
29144195 2018
140
Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? 61
30135630 2018
141
Central Serous Chorioretinopathy: Clinical Characteristics Associated with Visual Outcomes. 61
30067427 2018
142
Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy. 61
30050933 2018
143
Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels. 61
29518100 2018
144
Preputial mucosal graft for urethral repair. 61
28836924 2018
145
Vinclozolin induced epigenetic transgenerational inheritance of pathologies and sperm epimutation biomarkers for specific diseases. 61
30157260 2018
146
Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen. 61
29382326 2018
147
Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. 61
28836176 2017
148
[Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer]. 61
29325321 2017
149
The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition. 61
29372682 2017
150
Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. 61
29144897 2017
151
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. 61
28819703 2017
152
Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. 61
28965477 2017
153
Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells. 61
29187436 2017
154
Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. 61
28940538 2017
155
Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. 61
28699177 2017
156
Oxidative stress and prostatic diseases. 61
29181163 2017
157
Risk factors for contralateral inguinal hernia repair after unilateral inguinal hernia repair in male adult patients: analysis from a nationwide population based cohort study. 61
29157231 2017
158
Urinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity. 61
28764970 2017
159
Determinants of Behavioral Intentions to Screen for Prostate Cancer in Omani Men. 61
28966965 2017
160
Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study. 61
29211357 2017
161
Evaluation of the Efficacy of Post Prostatic Massage Urine Cytology in Diagnosis of Various Prostatic Lesions with Cytohistological and Clinical Correlation. 61
29118477 2017
162
MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology. 61
28130866 2017
163
Looking to the metabolic landscapes for prostate health monitoring. 61
28828350 2017
164
Traditional medicines and alternative practice in the management of prostate diseases in southern Ghana. 61
29622824 2017
165
Association between systemic inflammation and serum prostate-specific antigen in a healthy Korean population. 61
28861299 2017
166
Simultaneous Detection of Oral Pathogens in Subgingival Plaque and Prostatic Fluid of Men With Periodontal and Prostatic Diseases. 61
28548883 2017
167
Role of connexin 43 in cadmium-induced proliferation of human prostate epithelial cells. 61
28176351 2017
168
The potential of organoids in urological cancer research. 61
28534535 2017
169
[Gene regulation of prostaglandin synthase and prostate diseases]. 61
29723463 2017
170
Crocus sativus, Serenoa repens and Pinus massoniana extracts modulate inflammatory response in isolated rat prostate challenged with LPS. 61
28889734 2017
171
High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach. 61
28190704 2017
172
Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. 61
28139757 2017
173
Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. 61
28472278 2017
174
Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis. 61
28326819 2017
175
Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. 61
28191652 2017
176
Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer. 61
28187264 2017
177
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. 61
28530520 2017
178
A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. 61
28110975 2017
179
Computed tomography: a beneficial diagnostic tool for the evaluation of the canine prostate? 61
28482833 2017
180
Epithelial-mesenchymal transition in prostate cancer: an overview. 61
28430640 2017
181
Selective anti-proliferative activities of Carica papaya leaf juice extracts against prostate cancer. 61
28249253 2017
182
Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease. 61
28116672 2017
183
Prenatal and pubertal testosterone exposure imprint permanent modifications in the prostate that predispose to the development of lesions in old Mongolian gerbils. 61
26780870 2017
184
The role of prostatic inflammation in the development and progression of benign and malignant diseases. 61
27906778 2017
185
Environmental factors, epigenetics, and developmental origin of reproductive disorders. 61
27421580 2017
186
Optimizing structural and mechanical properties of cryogel scaffolds for use in prostate cancer cell culturing. 61
27987733 2017
187
Parental High-Fat Diet Promotes Inflammatory and Senescence-Related Changes in Prostate. 61
28261375 2017
188
68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review. 61
28217012 2017
189
Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. 61
27593477 2017
190
Fatigue, depression, and quality of life in patients with prostatic diseases. 61
28461987 2017
191
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. 61
28143503 2017
192
Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. 61
28289563 2017
193
Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. 61
27931798 2017
194
Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria. 61
28904679 2017
195
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. 61
27845125 2016
196
Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. 61
27749016 2016
197
Inducible expression of cancer-testis antigens in human prostate cancer. 61
27769045 2016
198
Human Papilloma Virus Detection by INNOLiPA HPV in Prostate Tissue from Men of Northeast Mexico 61
28030912 2016
199
Contribution of Caudal Müllerian Duct Mesenchyme to Prostate Development. 61
27595922 2016
200
Enhanced detection sensitivity of prostate-specific antigen via PSA-conjugated gold nanoparticles based on localized surface plasmon resonance: GNP-coated anti-PSA/LSPR as a novel approach for the identification of prostate anomalies. 61
27740614 2016
201
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. 61
27683107 2016
202
Immediate Continence Rates in RALRP: A Comparison of Three Techniques. 61
27777500 2016
203
Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. 61
27152882 2016
204
Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. 61
29320623 2016
205
Unfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer. 61
27453073 2016
206
Emerging medication for the treatment of male hypogonadism. 61
27552127 2016
207
Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. 61
27581270 2016
208
Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. 61
26976206 2016
209
ERG expression in prostate cancer: biological relevance and clinical implication. 61
26711283 2016
210
Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. 61
27172434 2016
211
Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. 61
27759820 2016
212
The role of the prostate in male fertility, health and disease. 61
27245504 2016
213
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. 61
27436144 2016
214
Glycosylation status of serum immunoglobulin G in patients with prostate diseases. 61
26880719 2016
215
DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. 61
26987799 2016
216
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. 61
27170414 2016
217
An observational Study of the Association between Androgenetic Alopecia and Size of the Prostate. 61
27601858 2016
218
The impact of obesity towards prostate diseases. 61
27014656 2016
219
A retrospective study of canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France. 61
26613854 2016
220
Associations between maternal phenolic exposure and cord sex hormones in male newborns. 61
26724800 2016
221
Uric acid: a modulator of prostate cells and activin sensitivity. 61
26910779 2016
222
The mouse prostate: a basic anatomical and histological guideline. 61
26773172 2016
223
Prevalence of erectile dysfunction in patients consulting urological clinics: multi-centric survey in the algerian west. 61
27532528 2016
224
An Analytical Study of Prostate-Specific Antigen Dynamics. 61
27956935 2016
225
[What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?] 61
28154664 2016
226
Prostate Cancer, High Cortisol Levels and Complex Hormonal Interaction. 61
27509946 2016
227
Locus-specific gene repositioning in prostate cancer. 61
26564800 2016
228
Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. 61
28066244 2016
229
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. 61
26296672 2016
230
Histochemical evaluation of postnatal lectin-binding sites in the mouse prostate. 61
27319301 2016
231
New transcription factors involved with postnatal ventral prostate gland development in male Wistar rats during the first week. 61
26549646 2015
232
The Effect of Testosterone on Men With Andropause. 61
26756004 2015
233
Contrast-enhanced ultrasonographic characteristics of the diseased canine prostate gland. 61
26277703 2015
234
Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience. 61
26593165 2015
235
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. 61
26497345 2015
236
Genistein reduces the noxious effects of in utero bisphenol A exposure on the rat prostate gland at weaning and in adulthood. 61
26260748 2015
237
Prenatal exposure to testosterone masculinises the female gerbil and promotes the development of lesions in the prostate (Skene's gland). 61
25483231 2015
238
Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. 61
26153112 2015
239
Epithelial and stromal alterations in prostate after cypermethrin administration in adult albino rats (histological and biochemical study). 61
25987297 2015
240
Testosterone Replacement Therapy on the Natural History of Prostate Disease. 61
26077355 2015
241
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. 61
25523493 2015
242
Ethnicity and Prostate Cancer in Southern Nigeria: A Preliminary Report. 61
26425060 2015
243
Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. 61
25845467 2015
244
[PATHOGENETIC TREATMENT OF CHRONIC NONBACTERIAL PROSTATITIS COMPLICATED BY SPERM DISORDERS]. 61
26665768 2015
245
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. 61
26171936 2015
246
Subspecialty training in andrology. 61
26048154 2015
247
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. 61
25554605 2015
248
Relationship Between Second to Fourth Digit Ratios and Benign Prostatic Hyperplasia in Aging Men. 61
26155515 2015
249
Knowledge and attitude of the population toward cancer prostate Riyadh, Saudi Arabia. 61
25837827 2015
250
Immunoelectron microscope localization of androgen receptors and proliferating cell nuclear antigen in the epithelial cells of albino rat ventral prostate. 61
30023185 2015
251
Assessing the utilization of functional imaging in multiparametric prostate MRI in routine clinical practice. 61
25578231 2015
252
Impact of comorbidity on 6-month hospital readmission and mortality after hip fracture surgery. 61
25627481 2015
253
Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. 61
29264129 2015
254
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. 61
25323935 2015
255
Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene. 61
25700984 2015
256
Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. 61
25632043 2015
257
DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. 61
25700986 2015
258
5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. 61
25239636 2015
259
Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. 61
25432062 2015
260
Morphology of treatment-related changes in the prostate and prostatic cancer. 61
26072634 2015
261
Association of Alcohol Consumption with Markers of Prostate Health and Reproductive Hormone Profiles: A Multi-Center Study of 4,535 Men in China. 61
26559058 2015
262
The influence of primary care quality on hospital admissions for people with dementia in England: a regression analysis. 61
25816231 2015
263
Cell kinetic studies fail to identify sequentially proliferating progenitors as the major source of epithelial renewal in the adult murine prostate. 61
26024527 2015
264
MMP-2 and MMP-9 activities and TIMP-1 and TIMP-2 expression in the prostatic tissue of two ethanol-preferring rat models. 61
26258010 2015
265
The effect of chronic prostatitis on zinc concentration of prostatic fluid and seminal plasma: a systematic review and meta-analysis. 61
26173049 2015
266
Enhancing Knowledge, Beliefs, and Intention to Screen for Prostate Cancer via Different Health Educational Interventions: a Literature Review. 61
26514484 2015
267
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL. 61
26225663 2015
268
Overexpression of periostin in stroma positively associated with aggressive prostate cancer. 61
25781169 2015
269
Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer. 61
24665929 2015
270
Oxidative stress in benign prostatic hyperplasia: a systematic review. 61
25503259 2015
271
Stem-cell-based therapy in the field of urology: a review of stem cell basic science, clinical applications and future directions in the treatment of various sexual and urinary conditions. 61
26243575 2015
272
Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers. 61
26090004 2015
273
Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases. 61
26417612 2015
274
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. 61
25035153 2014
275
The simultaneous detection of free and total prostate antigen in serum samples with high sensitivity and specificity by using the dual-channel surface plasmon resonance. 61
25016334 2014
276
In vitro modeling of the prostate cancer microenvironment. 61
24816064 2014
277
Xenotransplantation models to study the effects of toxicants on human fetal tissues. 61
25477288 2014
278
Hospital acquired blood stream infection as an adverse outcome for patients admitted to hospital with other principle diagnosis. 61
25538530 2014
279
The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage. 61
25372501 2014
280
Prostate cancer. Foreword. 61
25367319 2014
281
Prostate cancer immunotherapy: beyond immunity to curability. 61
25367978 2014
282
Male sexual function can be maintained without aromatization: randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months. 61
24751323 2014
283
Impact of cosmetic result on selection of surgical treatment in patients with localized prostate cancer. 61
25516703 2014
284
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. 61
26594314 2014
285
Prevalence of Trichomonas vaginalis by PCR in men attending a primary care urology clinic in South Korea. 61
25352707 2014
286
The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study. 61
24190367 2014
287
Management of lower urinary retention in a limited resource setting. 61
25489197 2014
288
Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: preliminary results. 61
24848289 2014
289
Late onset hypogonadism of men is not equivalent to the menopause. 61
25042874 2014
290
Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. 61
24830688 2014
291
[5ARI and PSA: therapeutic aspects]. 61
24744217 2014
292
[Benign prostatic hypertrophy and prostate cancer]. 61
25373266 2014
293
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. 61
24929891 2014
294
Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis. 61
24422606 2014
295
PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA. 61
26457269 2014
296
Metabolic syndrome and diabetes for the urologist. 61
25243043 2014
297
Factors influencing the acceptance of transrectal ultrasound-guided prostate biopsies. 61
25045444 2014
298
Identifying risk factors for surgical site complications after laparoscopic ventral hernia repair: evaluation of the Ventral Hernia Working Group grading system. 61
24773169 2014
299
Chronic pelvic pain: comorbidity between chronic musculoskeletal pain and vulvodynia. 61
24938200 2014
300
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. 61
24979481 2014
301
Diagnosis of common prostatic conditions in dogs: an update. 61
24947861 2014
302
Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. 61
24947855 2014
303
Promoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population. 61
24987558 2014
304
[Prostate stem cells: an update]. 61
24908740 2014
305
Overdetection in screening for prostate cancer. 61
24670870 2014
306
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. 61
24500928 2014
307
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. 61
24435840 2014
308
The prevalence of lower urinary tract symptoms in a Chinese population, and the correlation with uroflowmetry and disease perception. 61
24136186 2014
309
Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. 61
24338683 2014
310
BPH and prostate cancer risk. 61
24744523 2014
311
[In Process Citation]. 61
24670603 2014
312
Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. 61
24457841 2014
313
Primary non-Hodgkin follicular lymphoma of the prostate: A case report. 61
26328148 2014
314
Androgens and prostate disease. 61
24407178 2014
315
Recurrence and pseudorecurrence after laparoscopic ventral hernia repair: predictors and patient-focused outcomes. 61
24480213 2014
316
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. 61
25606581 2014
317
Nonsteroidal anti-inflammatory drugs and prostatic diseases. 61
24900965 2014
318
The continuous evolution of the Greenlight laser; the XPS generator and the MoXy laser fiber, expanding the indications for photoselective vaporization of the prostate. 61
23992242 2014
319
Lectin-binding sites in epithelial cells of the mouse prostate gland. 61
26004072 2014
320
New and experimental techniques in the treatment of benign prostatic diseases. 61
25782231 2014
321
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient. 61
24132461 2014
322
Lycopene for the prevention and treatment of prostate disease. 61
24531784 2014
323
MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases. 61
24115268 2014
324
New serum biomarkers for prostate cancer diagnosis. 61
25593898 2014
325
Knowledge and Perception of Nigerian Men 40 years and above Regarding Prostate Cancer. 61
26587514 2014
326
Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. 61
24001894 2013
327
Maturation of the developing human fetal prostate in a rodent xenograft model. 61
24038131 2013
328
Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer. 61
23421929 2013
329
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. 61
22608541 2013
330
Role of adhesion molecules and proliferation hyperplasic, pre neoplastic and neoplastic lesions in canine prostate. 61
24511741 2013
331
Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer. 61
24403231 2013
332
Normal canine prostate gland: repeatability, reproducibility, observer-dependent variability of ultrasonographic measurements of the prostate in healthy intact beagles. 61
23293870 2013
333
AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. 61
23864729 2013
334
Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epigenetic transgenerational inheritance of obesity. 61
24228800 2013
335
Serum PSA as a predictor of testosterone deficiency. 61
23859334 2013
336
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscesses. 61
23689049 2013
337
Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases. 61
24044092 2013
338
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. 61
23688836 2013
339
Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. 61
21872499 2013
340
The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. 61
23607319 2013
341
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. 61
23806388 2013
342
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. 61
23675780 2013
343
Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression. 61
23872639 2013
344
Formation of human prostate epithelium using tissue recombination of rodent urogenital sinus mesenchyme and human stem cells. 61
23852031 2013
345
Re: Involvement of estrogen receptors in prostatic diseases. 61
23663624 2013
346
Prostatic stromal neoplasms: differential diagnosis of cystic and solid prostatic and periprostatic masses. 61
23701087 2013
347
A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. 61
23389852 2013
348
Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008. 61
23713595 2013
349
Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. 61
23836950 2013
350
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. 61
23641775 2013
351
The male reproductive system - An overview of common problems. 61
23781524 2013
352
Laparoscopic ventral hernia repair: primary versus secondary hernias. 61
22795342 2013
353
Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. 61
23154423 2013
354
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. 61
23414693 2013
355
Current status of 5α-reductase inhibitors in prostate disease management. 61
23614056 2013
356
Autopsy study of prostatic weight and lesions in LUTH: a 12 month prospective study. 61
24579501 2013
357
Recent advances in prostate development and links to prostatic diseases. 61
23335485 2013
358
Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats. 61
22806172 2013
359
[Research on serum prostate-specific antigen measurement by characteristic spectral imaging method]. 61
23705449 2013
360
Androgens promote prostate cancer cell growth through induction of autophagy. 61
23250485 2013
361
Resveratrol in prostate diseases - a short review. 61
24579014 2013
362
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. 61
23300485 2013
363
Future prospects in the diagnosis and management of localized prostate cancer. 61
24163619 2013
364
Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. 61
23432584 2013
365
Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. 61
23359474 2013
366
Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production. 61
25374899 2013
367
Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification. 61
23308170 2013
368
[Urology. Trends in prostatic diseases in 2012]. 61
23409657 2013
369
Lack of liver X receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell. 61
23554947 2013
370
Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer. 61
24223413 2013
371
Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature. 61
24416569 2013
372
Male reproductive health disorders among Aboriginal and Torres Strait Islander men: a hidden problem? 61
23330768 2013
373
Clinico-pathological Correlation of Digital Rectal Examination Findings Amongst Nigerian Men with Prostatic Diseases: A Prospective Study of 236 Cases. 61
24027415 2013
374
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. 61
23690774 2013
375
Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostate. 61
23405234 2013
376
Expression of steroid 5α-reductase isozymes in prostate of adult rats after environmental stress. 61
23122426 2013
377
[Biopsy findings of low-risk prostate disease: are they real? Single centre experience]. 61
22729603 2012
378
Prostate Cancer and Prostatic Diseases (2012) 15, 313. 61
23147068 2012
379
Prenatal testosterone exposure as a model for the study of endocrine-disrupting chemicals on the gerbil prostate. 61
23239441 2012
380
Retinoic acid receptor β2 (RARβ2): nonivasive biomarker for distinguishing malignant versus benign prostate lesions from bodily fluids. 61
23294958 2012
381
Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies. 61
21889270 2012
382
[Evolution of prostatic surgical interventions: analysis of French national coding database]. 61
22999118 2012
383
Role of 5α-reductase inhibitors in benign prostatic diseases. 61
22333687 2012
384
Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men. 61
22648746 2012
385
Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. 61
23009291 2012
386
[Drug penetrability and etiologic diagnosis and treatment of prostatitis in men]. 61
23193661 2012
387
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. 61
22659250 2012
388
Senescence and steroid hormone receptor reactivities in accessory sex glands of elderly rats (Sprague-Dawley) following exogenous hormonal therapy. 61
22541803 2012
389
PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. 61
22874998 2012
390
Epigenetic markers of prostate cancer in plasma circulating DNA. 61
22619380 2012
391
DNA repair system and prostate cancer progression: the role of NBS1 polymorphism (rs1805794). 61
22413803 2012
392
[Neurophysiologic evaluation of patients with chronic prostatitis (III B chronic pain syndrome)]. 61
23116021 2012
393
Opioid-induced androgen deficiency (OPIAD). 61
22786453 2012
394
SU-E-T-615: Quantifying the Benefit of Adaptive Fractionation. 61
28517062 2012
395
Editorial comment to involvement of estrogen receptors in prostatic diseases. 61
22621219 2012
396
Involvement of estrogen receptors in prostatic diseases. 61
22375605 2012
397
[Sexual dysfunctions linked with prostatic diseases]. 61
22770495 2012
398
Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. 61
22425049 2012
399
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. 61
22339264 2012
400
[The relationship between oxidative stress and obesity in prostate disease]. 61
22522464 2012
401
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. 61
22233684 2012
402
Alterations of global histone H4K20 methylation during prostate carcinogenesis. 61
22413846 2012
403
Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. 61
22284307 2012
404
Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. 61
22209970 2012
405
The correlation between metabolic syndrome and prostatic diseases. 61
22119157 2012
406
Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. 61
22247499 2012
407
Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. 61
23049995 2012
408
Preventing Unnecessary Invasive Cancer-Diagnostic Tests: Changing the Cut-off Points. 61
23113134 2012
409
The Correlation between Diffusion-Weighted Imaging and Histopathological Evaluation of 356 Prostate Biopsy Sites in Patients with Prostatic Diseases. 61
22792487 2012
410
Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. 61
22514625 2012
411
Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. 61
22347418 2012
412
Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men. 61
22093190 2012
413
Dietary patterns and prostatic diseases. 61
22201864 2012
414
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. 61
21992222 2012
415
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. 61
21992404 2012
416
Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. 61
24009409 2012
417
Progress in gene therapy for prostate cancer. 61
23181221 2012
418
Botulinum toxin A in prostate disease: a venom from bench to bed-side. 61
22409179 2012
419
Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model. 61
23240022 2012
420
Estrogen receptor β activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. 61
22808245 2012
421
Prostate disease risk factors among a New Zealand cohort. 61
23363810 2012
422
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? 61
22848218 2012
423
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. 61
21826727 2012
424
[Relations between red cell structure, function and immune homeostasis in prostatic diseases]. 61
22646001 2012
425
Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. 61
21907698 2011
426
Adjuvant radiotherapy following radical prostatectomy for prostate cancer. 61
22161411 2011
427
What is the likelihood of requiring contralateral inguinal hernia repair after unilateral repair? 61
22000721 2011
428
In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay. 61
22019475 2011
429
Kappa statistics in the screening of malignancy of prostate. 61
22666930 2011
430
Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis. 61
22234006 2011
431
Cholesterol and benign prostate disease. 61
21862201 2011
432
The functional role of reactive stroma in benign prostatic hyperplasia. 61
21664759 2011
433
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. 61
22054323 2011
434
Examining risk perception among men with a family history of prostate cancer. 61
21310580 2011
435
Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system. 61
21827855 2011
436
Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer. 61
21631298 2011
437
Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men. 61
21382022 2011
438
Smooth muscle cell-specific knockout of androgen receptor: a new model for prostatic disease. 61
21733831 2011
439
Detecting gene-gene interactions in prostate disease in African American men. 61
21992608 2011
440
Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. 61
21684555 2011
441
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. 61
21624358 2011
442
Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules. 61
21489806 2011
443
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. 61
21656824 2011
444
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. 61
21091976 2011
445
Factors influencing quality of life after total laryngectomy: a study of 92 patients. 61
21845804 2011
446
Inflammation and benign prostatic hyperplasia: clinical implications. 61
21519898 2011
447
The complex interplay between cholesterol and prostate malignancy. 61
21798387 2011
448
Towards the prevention and management of prostatic diseases in Nigeria: a framework. 61
22135603 2011
449
The effects and prospects of the integration of traditional Chinese medicine and Western medicine on andrology in China. 61
21642998 2011
450
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. 61
21557269 2011
451
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆). 61
21554885 2011
452
Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. 61
21670775 2011
453
Bicycle riding: impact on lower urinary tract symptoms and erectile function in healthy men. 61
21811700 2011
454
The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. 61
21147815 2011
455
Prostatic disease and sexual dysfunction. 61
21750746 2011
456
Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. 61
26579287 2011
457
Increased levels of plasma haemoxygenase-1 in prostate cancer. 61
21263452 2011
458
[The role of functional condition of pelvic inferior muscles and corticospinal tract in urination disorders in prostatic diseases]. 61
21870479 2011
459
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. 61
20883781 2011
460
Estrogen action and prostate cancer. 61
21765856 2011
461
Precedence for prostate brachytherapy. 61
20729153 2011
462
[proPSA: a precursor of prostate-specific antigen, may improve the early diagnosis of prostate cancer]. 61
21678645 2011
463
Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. 61
21040364 2011
464
Prostate diseases--role of sex steroids and their inhibitors. 61
21397203 2011
465
Is testosterone a friend or a foe of the prostate? 61
21457469 2011
466
Association of Mycoplasma hominis infection with prostate cancer. 61
21471611 2011
467
Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor. 61
21262225 2011
468
Selective nanoparticle-directed ablation of the canine prostate. 61
21412805 2011
469
The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. 61
19762255 2011
470
Association of black race with follow-up of an abnormal prostate-specific antigen test. 61
21443067 2011
471
High-fat diet increases NF-κB signaling in the prostate of reporter mice. 61
20632379 2011
472
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. 61
20632317 2011
473
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. 61
21074211 2011
474
Effects of aging and ethnicity on serum free prostate specific antigen. 61
22320948 2011
475
The lady with raised prostate specific antigen: do we need to worry? 61
22292649 2011
476
Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. 61
22096650 2011
477
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. 61
21126868 2011
478
Role of inflammation in benign prostatic hyperplasia. 61
22110398 2011
479
Recent role of inflammation in prostate diseases: chemoprevention development opportunity. 61
21339547 2011
480
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. 61
21151972 2010
481
NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. 61
19771394 2010
482
Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. 61
20575982 2010
483
Early-life estrogens and prostate cancer in an animal model. 61
24795802 2010
484
Prostate Cancer and Prostatic Diseases. Editor's comments. 61
21068743 2010
485
[Distribution and significance of α1-adrenoceptor subtypes in patients with chronic prostatitis in prostate, bladder detrusor and posterior urethral tissue]. 61
21223784 2010
486
Intrinsic fluorescence of protoporphyrin IX from blood samples can yield information on the growth of prostate tumours. 61
20419341 2010
487
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. 61
21079217 2010
488
Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database. 61
20679895 2010
489
Prostate cancer screening perspective, Malaysia. 61
21062649 2010
490
The novel prostate cancer antigen 3 (PCA3) biomarker. 61
21176272 2010
491
The effectiveness of dried cranberries ( Vaccinium macrocarpon) in men with lower urinary tract symptoms. 61
20804630 2010
492
Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. 61
20941365 2010
493
Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome. 61
20927350 2010
494
1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. 61
20606040 2010
495
Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes. 61
21629532 2010
496
Effect of lycopene on androgen receptor and prostate-specific antigen velocity. 61
20819671 2010
497
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. 61
20647404 2010
498
[Study on interpretation of quantitative results of prostate-specific antigen using information theory]. 61
20805707 2010
499
Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. 61
20541241 2010
500
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. 61
20514437 2010
501
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. 61
20535861 2010
502
[Bacterial 16S rRNA genes and expression of IL-1β, TNF-α and IgA in prostate tissues]. 61
20979861 2010
503
Differential expression of genes in co-cultured versus separately cultured fibroblasts and epithelial cells from human benign hyperplastic prostate tissues. 61
20514417 2010
504
[Identification of Mycoplasma in patients with suspected prostate cancer]. 61
20799402 2010
505
Effect of anthropometric measurements and personal data parameters on benign prostatic hyperplasia and carcinoma prostate. 61
22338417 2010
506
Prostatic diseases in the senescence: structural and proliferative features. 61
20187843 2010
507
Polymorphisms in Toll-like receptor genes--implications for prostate cancer development. 61
20698170 2010
508
Comment on basal epithelial stem cells as efficient targets for prostate cancer initiation. 61
20529385 2010
509
Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. 61
20510305 2010
510
Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model? 61
20023690 2010
511
Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. 61
20102753 2010
512
ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. 61
20362939 2010
513
Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. 61
21209527 2010
514
Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis. 61
19728168 2010
515
Androgens and male aging: Current evidence of safety and efficacy. 61
20154699 2010
516
Human benign prostatic hyperplasia heterotransplants as an experimental model. 61
19946317 2010
517
Hormonal influences in prostate cancer: an update of a complex subject. 61
23965417 2010
518
Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. 61
20140087 2010
519
Effects of a prostate awareness pilot on GP consultations and PSA requests. 61
19942689 2010
520
Aromatase and regulating the estrogen:androgen ratio in the prostate gland. 61
19896534 2010
521
Diagnosing urological disorders in ageing men. 61
20307027 2010
522
Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). 61
20181284 2010
523
[Expressions of bacterial 16S rRNA, IL-1beta, TNF-alpha and NGF in prostate tissues]. 61
20180403 2010
524
Exploring older peoples' experiences of nocturia: a poorly recognised urinary condition that limits participation. 61
20302443 2010
525
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. 61
19912506 2010
526
Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data. 61
19579258 2009
527
[Prevalence of erectile dysfunction in patients consulting urological clinics: the ENJEU survey (one day national survey on prevalence of male sexual dysfunction among men consulting urologists)]. 61
19945668 2009
528
Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. 54
19541477 2009
529
Effect of spinal cord injury upon prostate: adenocarcinoma of prostate in a spinal cord injury patient - a case report. 61
20062548 2009
530
Clinicopathological behavior of single focus prostate adenocarcinoma. 61
19836800 2009
531
Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. 61
19375269 2009
532
An acute urinary retention in an old man caused by a giant Müllerian duct cyst: a case report. 61
19946447 2009
533
The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients. 61
19882057 2009
534
The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer. 61
19426190 2009
535
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. 61
19825806 2009
536
United States military contributions to the National Cancer Institute. 61
19720303 2009
537
[Optimisation of early diagnosis of prostatic diseases in megapolis setting]. 61
20213912 2009
538
Epigenetic transgenerational effects of endocrine disruptors on male reproduction. 61
19711250 2009
539
The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. 61
19720304 2009
540
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. 54
19375853 2009
541
Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. 61
19792969 2009
542
Prostatic perfusion in the dog using contrast-enhanced Doppler ultrasound. 61
19754598 2009
543
Cadmium concentration and metallothionein expression in prostate cancer and benign prostatic hyperplasia of humans. 61
19586829 2009
544
Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia. 61
19570489 2009
545
Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians. 61
19636411 2009
546
Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. 61
18280636 2009
547
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? 61
19578352 2009
548
[Chronic prostatitis and biofilm]. 61
19696557 2009
549
Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. 61
19436293 2009
550
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. 61
19267353 2009
551
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? 61
19543428 2009
552
Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. 61
19199789 2009
553
Role of the renin-angiotensin system in prostate cancer. 61
18824067 2009
554
Dystroglycan patterns on the prostate of non-obese diabetic mice submitted to glycaemic control. 61
19335554 2009
555
A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. 61
19150562 2009
556
High-fat diet, obesity and prostate disease: the ATX-LPA axis? 61
19204739 2009
557
Testosterone deficiency syndrome: treatment and cancer risk. 61
19429438 2009
558
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. 61
19252750 2009
559
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. 61
18942119 2009
560
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. 61
19228530 2009
561
AHR signaling in prostate growth, morphogenesis, and disease. 61
18977204 2009
562
The dual, opposing roles of estrogen in the prostate. 61
19250203 2009
563
Saw palmetto extract induces nuclear heterogeneity in mice. 61
21783933 2009
564
Prostate Cancer and Prostatic Diseases. Report from Durham. 61
19204722 2009
565
Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. 54
19152248 2009
566
Perspective of Botox for treatment of male lower urinary tract symptoms. 61
19057212 2009
567
Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. 61
19440015 2009
568
Incidence of inguinal hernia after prostate surgery: open radical retropubic prostatectomy versus open simple prostatectomy versus transurethral resection of the prostate. 61
19120532 2009
569
Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. 54
18579171 2008
570
Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. 61
18718734 2008
571
Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. 61
19512848 2008
572
Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. 61
19149228 2008
573
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. 61
19205388 2008
574
[Complications using the laser]. 61
19140597 2008
575
Participation of caudal müllerian mesenchyma in prostate development. 61
18801537 2008
576
Androgen receptor CAG repeat polymorphisms in canine prostate cancer. 61
18783352 2008
577
Enhancement characteristics of benign and malignant focal peripheral nodules in the peripheral zone of the prostate gland studied using contrast-enhanced transrectal ultrasound. 61
18774354 2008
578
Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men. 61
18843748 2008
579
Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. 54
18820278 2008
580
Inhibition of prostate efferent neurotransmission by amikacin. 61
18512731 2008
581
[Efficacy of vitaprost forte in patients with prostatic adenoma]. 61
19069497 2008
582
Minireview: regulation of prostatic stem cells by stromal niche in health and disease. 61
18535102 2008
583
Androgen deprivation by activating the liver X receptor. 61
18450964 2008
584
Lignans isolated from Campylotropis hirtella (Franch.) Schindl. decreased prostate specific antigen and androgen receptor expression in LNCaP cells. 61
18656936 2008
585
A novel splice variant of the nuclear coactivator p120 functions strongly for androgen receptor: characteristic expression in prostate disease. 61
18560202 2008
586
Educating patients about lifestyle modifications for prostate health. 61
18675616 2008
587
Prostate development: a historical perspective. 61
18462432 2008
588
Gene expression profiling in the developing prostate. 61
18462436 2008
589
Differential proteomics in the aging Noble rat ventral prostate. 61
18546156 2008
590
Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. 61
18403105 2008
591
Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA. 61
18489403 2008
592
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 61
18405753 2008
593
Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. 61
18302221 2008
594
[Official statistics on urological morbidity in the Russian Federation]. 61
18672498 2008
595
Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. 61
18497498 2008
596
Prostate stem cells: the niche and cell markers. 61
18380813 2008
597
Circulating PSA-containing macrophages as a possible target for the detection of prostate cancer: a three-color/five-parameter flow cytometric study on peripheral blood samples. 61
18343793 2008
598
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. 61
18471794 2008
599
Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease. 61
18220299 2008
600
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. 61
18280514 2008
601
[Prostatic diseases in elderly men: contemporary diagnosis and treatment of cancer and benign hyperplasia of the prostate]. 61
18441479 2008
602
Biomarkers for early prostate cancer detection. 61
18427435 2008
603
The role of estrogens and estrogen receptors in normal prostate growth and disease. 61
18093629 2008
604
Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. 61
18207193 2008
605
The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer. 61
18084254 2008
606
The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men. 61
17850358 2008
607
Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. 61
18194690 2008
608
[Results of German "Men's Health Awareness Days" in 2006]. 61
18231772 2008
609
[Analysis of the results of percent free prostate specific antigen detection among the men without prostate diseases in Xi'an]. 61
18250060 2008
610
Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. 61
18226066 2008
611
Correlates of urinary, fecal, and dual incontinence in older African-American and white men and women. 61
18070007 2008
612
Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer? 61
17907049 2008
613
Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases? 61
18288584 2008
614
[Curcumin in the treatment of prostatic diseases]. 61
18297817 2008
615
[Capacities of complex ultrasound study in the diagnosis of prostate cancer]. 61
22187902 2008
616
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study. 54
17997422 2008
617
PROBE: patient and physician behaviour and education in prostate disease. 61
18173808 2008
618
Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. 61
17803183 2008
619
The use of botulinum neurotoxin type A (BoNTA) in urology. 61
18322639 2008
620
Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry. 61
19013358 2008
621
Epigenetic programming of the germ line: effects of endocrine disruptors on the development of transgenerational disease. 61
18252044 2008
622
Testosterone for the aging male; current evidence and recommended practice. 61
18488876 2008
623
Testosterone levels in benign prostatic hypertrophy and prostate cancer. 61
18362481 2008
624
HLA class II antigen presentation by prostate cancer cells. 61
17938645 2008
625
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats. 61
18379994 2008
626
Training in male sexual and reproductive health for a primary care physician. 61
25606115 2008
627
Nutraceuticals in Prostate Disease: The Urologist's Role. 61
18836556 2008
628
Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography. 61
18029918 2007
629
Prevention of urinary and fecal incontinence in adults. 61
18457475 2007
630
An assessment of the virtual conversations method for prostate cancer patient education. 61
18217532 2007
631
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. 61
17886252 2007
632
[Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma]. 61
18649662 2007
633
Surgical management of common canine prostatic conditions. 61
18210976 2007
634
Transperineal ultrasound for measurement of prostate volume: validation against transrectal ultrasound. 61
17706715 2007
635
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. 61
17702894 2007
636
Inflammation and chronic prostatic diseases: evidence for a link? 61
17618043 2007
637
The role of inflammation and infection in the pathogenesis of prostate carcinoma. 61
17662075 2007
638
Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. 61
17614338 2007
639
S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study. 61
17626245 2007
640
Do people want to be autonomous patients? Preferred roles in treatment decision-making in several patient populations. 61
17678513 2007
641
Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders. 61
17880832 2007
642
Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. 61
17766643 2007
643
Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. 61
17632170 2007
644
[Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease]. 61
17953381 2007
645
Patterns of self-referral in men with symptoms of prostate disease. 61
17640454 2007
646
Enlarged prostate: BPH could be two diseases, one more severe. Diagnostic breakthrough could identify new form of prostate disease sooner, enabling earlier therapy. 61
17695663 2007
647
Epigenetic transgenerational actions of vinclozolin on the development of disease and cancer. 61
17956218 2007
648
Development of a meat frequency questionnaire for use in diet and cancer studies. 61
17659903 2007
649
Treating prostate cancer: a rationale for targeting local oestrogens. 61
17611544 2007
650
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. 61
17495178 2007
651
The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. 61
17492653 2007
652
[Diffusion weighted imaging: its diagnostic and differential value for prostate cancer]. 61
17725302 2007
653
Hedgehog signaling in prostate growth and benign prostate hyperplasia. 61
18519011 2007
654
Canine subclinical prostatic disease: histological prevalence and validity of digital rectal examination as a screening test. 61
17941597 2007
655
Psagraph: a simple graphical and useful tool for follow-up and decision on biopsy and treatment of patients with prostatic diseases. 61
17437449 2007
656
Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners. 61
17511723 2007
657
Diagnosing prostate cancer - what GPs need to know. 61
17492070 2007
658
Experimental alcoholism and pathogenesis of prostatic diseases in UChB rats. 61
17188526 2007
659
Endocrine disruptors and epigenetic transgenerational disease etiology. 61
17413841 2007
660
[Vitaprost forte in the therapy of patients with prostatic adenoma]. 61
17722619 2007
661
Experimental study on the effect of high-intensity focused ultrasound (HIFU) using Sonablate-500 in the ablation of canine prostate. 61
17497295 2007
662
Factors related to use of prostate cancer screening: the Alberta Tomorrow Project. 61
20101288 2007
663
LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. 61
17317883 2007
664
Molecular markers for prostate cancer. 61
17303324 2007
665
Screening for prostate cancer: a Cochrane systematic review. 61
17206534 2007
666
Long-term follow-up of a randomized clinical trial of non-mesh versus mesh repair of primary inguinal hernia. 61
17279491 2007
667
Spectrum of urological procedures in University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria. 61
17668720 2007
668
Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL. 61
17488533 2007
669
[Transient receptor potential ion channels and prostatic diseases]. 61
17393789 2007
670
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics. 54
17320672 2007
671
The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. 61
17005316 2007
672
Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. 61
17253195 2007
673
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. 61
17194448 2007
674
Effects of soy phytoestrogens on the prostate. 61
17310260 2007
675
Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. 61
17270658 2007
676
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. 61
17044071 2007
677
Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution). 61
18044088 2007
678
Point-of-care PSA testing: an evaluation of PSAwatch. 61
17353914 2007
679
Cryosurgery: A review. 61
22477240 2007
680
Oxytocin and the human prostate in health and disease. 61
17725969 2007
681
Citrate in expressed prostatic secretions has the feasibility to be used as a useful indicator for the diagnosis of category IIIB prostatitis. 61
17406132 2007
682
Estrogens and aspects of prostate disease. 61
17199853 2007
683
The clinical features of anterior prostate cancers. 61
17026586 2006
684
Hepatotoxicity induced by cyproterone acetate: a report of three cases. 61
17167851 2006
685
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. 61
17085105 2006
686
Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. 61
16973726 2006
687
Prostate cancer risk in testosterone-treated men. 61
17113983 2006
688
Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. 61
17107848 2006
689
Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? 54
17052442 2006
690
Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate. 61
17031809 2006
691
Morphometric and morphological features of the ventral prostate in rats submitted to chronic nicotine and alcohol treatment. 61
17014878 2006
692
Men in Australia Telephone Survey (MATeS): predictors of men's help-seeking behaviour for reproductive health disorders. 61
17137429 2006
693
Positive effect of prostaglandin on regulation of prostatic blood flow. 61
17010733 2006
694
Polymerase chain reaction-based identification of Propionibacterium acnes types isolated from the male urinary tract: evaluation of adolescents, normal adults and men with prostatic pathology. 61
16879683 2006
695
Injectables for the treatment of stress urinary incontinence: current use and future perspectives. 61
16859427 2006
696
Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. 61
16644920 2006
697
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. 61
16820871 2006
698
Prevalence of hypogonadism in males aged at least 45 years: the HIM study. 61
16846397 2006
699
Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. 61
16740699 2006
700
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. 54
16686717 2006
701
Bladder lithiasis: from open surgery to lithotripsy. 61
16470391 2006
702
Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. 61
16522744 2006
703
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. 61
16600802 2006
704
Update on outcomes research databases in prostate cancer 2006. 61
16679854 2006
705
Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. 61
16614113 2006
706
A preliminary analysis and model of prostate injection distributions. 61
16302267 2006
707
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. 61
16729916 2006
708
Sexual activity, prevalence of sexual problems, and associated help-seeking patterns in men and women aged 40-80 years in Korea: data from the Global Study of Sexual Attitudes and Behaviors (GSSAB). 61
16490013 2006
709
Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer. 54
16643633 2006
710
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. 61
16417966 2006
711
Aromatase and prostate cancer. 61
16498360 2006
712
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases. 61
16173032 2006
713
Stents for prostatic diseases: any progress after 25 years? 61
16413667 2006
714
Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. 61
15882928 2006
715
Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. 61
16114065 2006
716
Role of 5 alpha-reductase inhibitors in the management of prostate cancer. 54
18046919 2006
717
Changes in gap junctional connexin isoforms during prostate cancer progression. 61
16114058 2006
718
Treatment- and disease-related complications of prostate cancer. 61
17021643 2006
719
Risk factors for benign prostatic hyperplasia in South Korean men. 61
16401915 2006
720
Turbulent urinary flow in the urethra could be a causal factor for benign prostatic hyperplasia. 61